RxDoctor Payments Data

Kipper Jones

Family · Tyler, TXNPI 1134793938

Payments from drug & device makers

$2,001in general payments, 2019–2025

Across 76 payments — averaging $26.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$371
  • Axonics, Inc.$361
  • Sumitomo Pharma America, Inc.$276
  • Urovant Sciences Inc$189
  • 180 Medical, Inc.$177
  • Avanos Medical$124
  • plus $504 from 11 others

What the payments were for

  • Food & beverage$2,001100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)21$371
Axonics, Inc.8$361
Sumitomo Pharma America, Inc.12$276
Urovant Sciences Inc8$189
180 Medical, Inc.8$177
Avanos Medical1$124
GE HealthCare1$111
Blue Earth Diagnostics1$100
Johnson & Johnson2$49
Astellas Pharma US Inc3$46
Teleflex LLC2$43
Hollister Incorporated2$41
Accord Healthcare, Inc.2$32
Urogen Pharma, Inc.2$32
Coloplast1$19
ABC Home Medical Supply, Inc.1$17
Tolmar, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,001 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$53,263
Medicare patients
458
Services billed
871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron235$148,777
GemtesaVibegron79$48,579
Mirabegron ErMirabegron39$19,683
ElmironPentosan Polysulfate Sodium13$13,182
Tamsulosin Hcl482$6,207
Estradiol42$4,595
Oxybutynin Chloride ErOxybutynin Chloride267$4,160
Methenamine Hippurate51$4,028
Trospium Chloride52$2,670
Solifenacin Succinate49$2,663
Potassium Citrate ErPotassium Citrate29$2,167
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst66$1,342
Finasteride109$1,283
CefuroximeCefuroxime Axetil67$1,201
Doxycycline Hyclate72$1,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$46$148,777235 claims
Sumitomo Pharma America, Inc.Gemtesa$276$48,57979 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →